Analyst Reco. Pfizer Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:03:13 05/06/2026 BST			5-day change	1st Jan Change
26.04 ^USD	+1.36%		-0.53%	+4.58%

06-06	Pfizer Presents Detailed Results From Multiple Phase 2b Studies Of Berobenatide And Plans To Advance 10 Phase 3 Studies For Chronic Weight Management And Obesity-Related Comorbidities	CI
06-06	Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial	RE

Analyst Reco.

06-01	PFIZER INC : Jefferies remains its Buy rating	ZD
06-01	PFIZER INC : JP Morgan remains Neutral	ZD
05-28	PFIZER INC : Barclays reiterates its Sell rating	ZD
05-18	Daiwa Securities Adjusts Price Target on Pfizer to $28 From $27, Maintains Neutral Rating	MT
05-06	PFIZER INC : DZ Bank reiterates its Buy rating	ZD
05-06	PFIZER INC : UBS remains Neutral	ZD
05-06	PFIZER INC : Jefferies reaffirms its Buy rating	ZD
05-06	Leerink Partners Adjusts Price Target on Pfizer to $28 From $26	MT
05-05	PFIZER INC : JP Morgan reaffirms its Neutral rating	ZD
04-28	Citigroup Lifts Price Target on Pfizer to $27 From $26, Maintains Neutral Rating	MT
04-28	Jefferies Adjusts Price Target on Pfizer to $35 From $34, Maintains Buy Rating	MT
04-23	Rothschild & Co Redburn Adjusts Price Target on Pfizer to $24 From $25, Maintains Neutral Rating	MT
04-20	Pfizer's Upcoming Tafamidis Bench Trial Shows Asymmetric Upside, RBC Capital Markets Says	MT
04-16	CICC Initiates Pfizer at Outperform With $33 Price Target	MT
04-13	UBS Raises Price Target on Pfizer to $27 From $25, Maintains Neutral Rating	MT
04-13	BMO Capital Adjusts Price Target on Pfizer to $34 From $30, Maintains Outperform Rating	MT
04-10	PFIZER INC : Gets a Neutral rating from JP Morgan	ZD
04-09	BofA Adjusts Price Target on Pfizer to $26 From $27, Maintains Neutral Rating	MT
03-24	PFIZER INC : Jefferies keeps its Buy rating	ZD
03-24	Guggenheim Adjusts Pfizer's PT to $36 From $35, Keeps Buy Rating	MT
03-17	HSBC Adjusts Price Target on Pfizer to $32 From $29, Maintains Buy Rating	MT
03-10	PFIZER INC : UBS is Neutral	ZD
02-20	Barclays Initiates Coverage on Pfizer With Underweight Rating	MT
02-17	Rothschild & Co Redburn Adjusts Price Target on Pfizer to $25 From $23, Maintains Neutral Rating	MT
02-12	Daiwa Securities Downgrades Pfizer to Neutral From Outperform, Price Target is $27	MT